Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics

Neuropsychopharmacology

Volumn 21, Issue 3, 1999, Pages 372-379

  Prince, Jonathan A ^a   Blennow, Kaj ^a   Gottfries, Carl G ^b   Karlsson, Ingvar ^b   Oreland, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Institute of Clinical Neuroscience   (Sweden)

Author keywords

Cytochrome c oxidase; Human brain; Mitochondria; Neuroleptics; Schizophrenia

Indexed keywords

CYTOCHROME C OXIDASE; NEUROLEPTIC AGENT;

AGED; ARTICLE; BASAL GANGLION; BRAIN MITOCHONDRION; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; MALE; MESENCEPHALON; MITOCHONDRIAL RESPIRATION; MOTOR PERFORMANCE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; BASAL GANGLIA; CAUDATE NUCLEUS; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; NADH DEHYDROGENASE; NUCLEUS ACCUMBENS; PUTAMEN; SCHIZOPHRENIA; SUCCINATE DEHYDROGENASE;

EID: 0032775671     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00016-0     Document Type: Article

References (38)

1. Ackrell B.A., Kearney E.B., Singer T.P. Mammalian succinate dehydrogenase. Methods Enzymol. 53:1978;466-483.
2. Andreasen N.C., O'Leary D.S., Cizadlo T., Arndt S., Rezai K., Ponto L.L., Watkins G.L., Hichwa R.D. Schizophrenia and cognitive dysmetria. A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry Proc Natl Acad Sci U S A. 93(18):1996;9985-9990.
3. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Hypofrontality in schizophrenia. Distributed dysfunctional circuits in neuroleptic-naive patients Lancet. 349(9067):1997;1730-1734.
4. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 31:1992;119-130.
5. Buchsbaum M.S., Haier R.J., Potkin S.G., Nuechterlein K., Bracha H.S., Katz M., Lohr J., Wu J., Lottenberg S., Jerabek P.A., Trenary M., Tafalla R., Reynolds C., Bunney W.E. Fontostriatal disorder of cerbral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry. 49:1992;935-942.
6. Buchsbaum M.S., Ingvar D.H., Kessler R., Waters R.N., Cappelletti J., van Kammen D.P., King A.C., Johnson J.L., Manning R.G., Flynn R.W., Mann L.S., Bunney W.E. Jr., Sokoloff L. Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry. 39:1982;251-259.
7. Buchsbaum M.S., Wu J.C., DeLisi L.E., Holcomb H.H., Hazlett E., Cooper-Langston K., Kessler R. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects. differences between normal controls and schizophrenic patients Biol Psychiatry. 22(4):1987;479-494.
8. Cavelier L., Jazin E.E., Eriksson I., Prince J., Bave U., Oreland L., Gyllensten U. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics. 29:1995;217-224.
9. Clark C.M., Kessler R., Buchsbaum M.S., Margolin R.A., Holcomb H.H. Correlational methods for determining regional coupling of cerebral glucose metabolism. A pilot study Biol Psychiatry. 19(5):1984;663-678.
10. Cleghorn J.M., Garnett E.S., Nahmias C., Firnau G., Brown G.M., Kaplan R., Szechtman H., Szechtman B. Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res. 28(2):1989;119-133.
11. DeLisi L.E., Holcomb H.H., Cohen R.M., Pickar D., Carpenter W., Morihisa J.M., King A.C., Kessler R., Buchsbaum M.S. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab. 5(2):1985;201-206.
12. Downs T.R., Wilfinger W.W. Fluorometric quantification of DNA in cells and tissue. Anal Biochem. 131:1983;538-547.
13. Early T.S., Reiman E.M., Raichle M.E., Spitznagel E.L. Left globus pallidus abnormality in never-medicated pa-tients with schizophrenia. Proc Natl Acad Sci U S A. 84(2):1987;561-563.
14. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull. 23(3):1997;437-458.
15. Hevner R.F., Duff R.S., Wong Riley M.T.T. Coordination of ATP production and consumption in brain. Parallel regulation of cytochrome oxidase and Na+,K+-ATPase Neurosci Lett. 138:1992;188-192.
16. Holcomb H.H., Cascella N.G., Thaker G.K., Medoff D.R., Dannals R.F., Tamminga C.A. Functional sites of neuroleptic drug action in the human brain. PET/FDG studies with and without haloperidol Am J Psychiat. 153:1996;41-49.
17. Katz M., Buchsbaum M.S., Siegel B.V. Jr., Wu J., Haier R.J., Bunney W.E. Jr. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. Neuropsychobiology. 33(1):1996;1-11.
18. Kung L., Conley R., Chute D.J., Smialek J., Roberts R.C. Synaptic changes in the striatum of schizophrenic cases. A controlled postmortem ultrastructural study Synapse. 28:1998;125-139.
19. Levy R., Friedman H.R., Davachi L., Goldman-Rakic P.S. Differential activation of the caudate nucleus in primates performing spatial and nonspatial working memory tasks. J Neurosci. 17(10):1997;3870-3882.
20. Markwell M.A.C., Maas S.M., Biebar L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and in protein samples. Anal Biochem. 87:1978;206-211.
21. Miller D.D., Andreasen N.C., O'Leary D.S., Rezai K., Watkins G.L., Ponto L.L., Hichwa R.D. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology. 17(4):1997;230-240.
22. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:1990;254-258.
23. Prince J.A., Yassin M.S., Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharm Exp Ther. 280:1997;261-267. a.
24. Prince J.A., Yassin M.S., Oreland L. A histochemical demonstration of altered cytochrome oxidase activity in the rat brain by neuroleptics. Eur Neuropsychopharmacol. 8:1997;1-6. b.
25. Prince J.A., Yassin M., Oreland L. Normalization of cytochrome-c oxidase activity in the rat brain by neuroleptics after chronic treatment with PCP or methamphetamine. Neuropharmacology. 36(11/12):1997;1665-1678. c.
26. Rago R., Mitchen J., Wilding G. DNA fluorometric assay in 96-well tissue culture plates using hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem. 191:1990;31-34.
27. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry. 55:1998;235-243.
28. Siegel B.V. Jr., Buchsbaum M.S., Bunney W.E. Jr., Gottschalk L.A., Haier R.J., Lohr J.B., Lottenberg S., Najafi A., Nuechterlein K.H., Potkin S.G. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry. 150(9):1993;1325-1336.
29. Singer V.L., Jones L.J., Yue S.T., Haugland R.P. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem. 249(2):1997;228-238.
30. Tamminga C.A., Thaker G.K., Buchanen R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry. 49:1992;522-530.
31. Whitfield C.D., Bostedor R., Goodrunt D., Haak N., Chu E.H.Y. Hamster cell mutants unable to grow on galactose and exhibiting an overlapping complementation pattern are defective in the electron transport chain. J Biol Chem. 256(13):1981;6651-6656.
32. Wiesel F.A., Wik G., Sjogren I., Blomqvist G., Greitz T. Altered relationships between metabolic rates of glucose in brain regions of schizophrenic patients. Acta Psychiatr Scand. 76(6):1987;642-647.
33. Wolkin A., Jaeger J., Brodic J.D., Wolf A.P., Fowler J., Rotrosen J., Gomez-Mont F., Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry. 142(5):1985;564-571.
34. Wolkin A., Sanfilipo M., Duncan E., Angrist B., Wolf A.P., Cooper T.B., Brodie J.D., Laska E., Rotrose Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. 153(3):1996;346-354.
35. Wong-Riley M. Changes in the visual system of monocularly sutured or enucleated cats demonstrable with cytochrome oxidase histochemistry. Brain Res. 171:1979;11-28.
36. Wong-Riley M. Cytochrome Oxidase. an endogenous metabolic marker for neuronal activity TINS. 12:1989;94-101.
37. Wong-Riley M., Carrol E.W. Effect of impulse blockage on cytochrome oxidase activity in monkey visual system. Nature. 307:1984;262-264.
38. Yonetani T., Ray G. Studies on cytochrome oxidase. J Biol Chem. 240(8):1965;3392-3399.